Please ensure Javascript is enabled for purposes of website accessibility

4 Senior Executives Are Leaving Sanofi Following New CEO's Strategic Overhaul

By Mark Prvulovic – Feb 11, 2020 at 4:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Big changes are on the horizon for this pharmaceutical giant.

News broke on Tuesday morning that four top executives from Sanofi (SNY -0.10%) will be leaving the company as part of a broader strategic shift from Sanofi's new CEO. Bloomberg reported that the departing executives are Ameet Nathwani, the company's chief medical officer and chief digital officer, Dieter Weinard, executive vice president (EVP) of primary care, Kathleen Tregoning, EVP of external affairs, and Dominique Carouge, EVP of business transformation.

The departures are seen as a consequence of Sanofi's new CEO, Paul Hudson, who is working to revamp the healthcare giant's corporate strategy. He was hired in September 2019 and since then has implemented a number of changes in the company.

An older person in a suit packing his belongings in a cardboard box.

Image source: Getty Images.

One of those changes include the slimming down of the size of Sanofi's executive committee. Although it's uncertain how many executives will be leaving the company, Hudson reportedly expects the new executive structure for the company to be fully in place by the second quarter.

A new strategy for growth

In December, Hudson announced a new vision for the company, which would prioritize growth from key business segments, including its vaccines as well as Dupixent, a treatment for patients with atopic dermatitis (eczema) and asthma.

Wall Street remains optimistic about Dupixent's potential, with some analysts saying Dupixent could see peak drug sales of as much as $10.9 billion annually. "We see Dupixent beating consensus in the near term with a faster asthma ramp and high treatment persistence in atopic dermatitis despite forthcoming competition," wrote SVB Leerink analyst Geoffrey Porges on Tuesday.

Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
$38.86 (-0.10%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.